JP2018510857A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510857A5
JP2018510857A5 JP2017546173A JP2017546173A JP2018510857A5 JP 2018510857 A5 JP2018510857 A5 JP 2018510857A5 JP 2017546173 A JP2017546173 A JP 2017546173A JP 2017546173 A JP2017546173 A JP 2017546173A JP 2018510857 A5 JP2018510857 A5 JP 2018510857A5
Authority
JP
Japan
Prior art keywords
imidazol
alkyl
fluorophenyl
imidazo
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510857A (ja
JP6836998B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019830 external-priority patent/WO2016140884A1/en
Publication of JP2018510857A publication Critical patent/JP2018510857A/ja
Publication of JP2018510857A5 publication Critical patent/JP2018510857A5/ja
Application granted granted Critical
Publication of JP6836998B2 publication Critical patent/JP6836998B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546173A 2015-03-02 2016-02-26 TGF−β阻害剤 Expired - Fee Related JP6836998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127109P 2015-03-02 2015-03-02
US62/127,109 2015-03-02
PCT/US2016/019830 WO2016140884A1 (en) 2015-03-02 2016-02-26 TGF-β INHIBITORS

Publications (3)

Publication Number Publication Date
JP2018510857A JP2018510857A (ja) 2018-04-19
JP2018510857A5 true JP2018510857A5 (enExample) 2019-04-04
JP6836998B2 JP6836998B2 (ja) 2021-03-03

Family

ID=55543068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546173A Expired - Fee Related JP6836998B2 (ja) 2015-03-02 2016-02-26 TGF−β阻害剤

Country Status (23)

Country Link
US (3) US9884868B2 (enExample)
EP (1) EP3265454B1 (enExample)
JP (1) JP6836998B2 (enExample)
KR (1) KR20170122799A (enExample)
CN (1) CN107406412B (enExample)
AR (1) AR103828A1 (enExample)
AU (1) AU2016226468B2 (enExample)
BR (1) BR112017017135A2 (enExample)
CA (1) CA2973602A1 (enExample)
CL (1) CL2017002207A1 (enExample)
CO (1) CO2017009891A2 (enExample)
EA (1) EA037112B1 (enExample)
ES (1) ES2789331T3 (enExample)
IL (1) IL254187A0 (enExample)
MX (1) MX371167B (enExample)
MY (1) MY186133A (enExample)
PE (1) PE20171789A1 (enExample)
PH (1) PH12017501326A1 (enExample)
SG (1) SG11201705821XA (enExample)
TN (1) TN2017000374A1 (enExample)
TW (1) TW201639827A (enExample)
WO (1) WO2016140884A1 (enExample)
ZA (1) ZA201705527B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845745B2 (en) 2017-03-23 2023-12-19 Clavius Pharmaceuticals, LLC. Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265454B1 (en) 2015-03-02 2020-02-26 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018107072A1 (en) 2016-12-08 2018-06-14 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
ES2918448T3 (es) 2018-03-29 2022-07-15 Univ Masarykova 4-(1H-Imidazol-5-il)-1H-pirrolo [2,3-b]piridinas para su uso en el tratamiento de leucemias, linfomas y tumores sólidos
JP7540994B2 (ja) 2018-07-11 2024-08-27 スカラー ロック インコーポレイテッド 高親和性のアイソフォーム選択的TGFβ1阻害剤、およびその使用
US12077548B2 (en) 2018-08-22 2024-09-03 Clavius Pharmaceuticals, LLC. Substituted imidazoles for the inhibition of TGF-β and methods of treatment
CN113195467A (zh) * 2018-12-11 2021-07-30 施万生物制药研发Ip有限责任公司 适用作alk5抑制剂的萘啶和喹啉衍生物
CN111825658B (zh) * 2019-04-18 2024-11-08 华东理工大学 Egfr三突变抑制剂及其应用
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
JP2023502662A (ja) * 2019-11-22 2023-01-25 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Alk5阻害剤としての置換1,5-ナフチリジンまたはキノリン
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4165041A1 (en) * 2020-06-10 2023-04-19 Theravance Biopharma R&D IP, LLC Naphthyridine derivatives useful as alk5 inhibitors
CN112321592B (zh) * 2020-11-12 2022-03-04 山东省科学院菏泽分院 一种6-氯咪唑并[1,2-b]哒嗪-3-甲腈的合成方法
WO2022251359A1 (en) * 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
KR20230017756A (ko) * 2021-07-28 2023-02-06 주식회사 티움바이오 종양 예방 또는 치료용 약학 조성물 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2024239186A1 (zh) * 2023-05-22 2024-11-28 睿健医药科技(苏州)有限公司 吡唑甲酰基哌嗪酮类化合物、药物组合物及其应用
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025063820A1 (ko) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 폐섬유화증 치료용 조성물
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
KR20250144822A (ko) * 2024-03-27 2025-10-13 동국대학교 산학협력단 신규 옥사졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
CA2440211A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
DE60309342T2 (de) 2002-08-09 2007-05-16 Eli Lilly And Co., Indianapolis Benzimidazole und benzothiazole als inhibitoren der map-kinase
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
WO2005080380A1 (en) * 2004-02-03 2005-09-01 Eli Lilly And Company Kinase inhibitors
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
SI1962830T1 (sl) * 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008154241A1 (en) * 2007-06-08 2008-12-18 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
EP2170337A4 (en) * 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PL2949670T3 (pl) 2009-12-10 2019-07-31 F. Hoffmann-La Roche Ag Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9221910B2 (en) 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
AU2011248083B2 (en) 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
US8980933B2 (en) * 2010-05-05 2015-03-17 Universitat Bayreuth Combretastatin analogs for use in the treatment of cancer
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
NO2694640T3 (enExample) 2011-04-15 2018-03-17
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
WO2013007708A1 (en) * 2011-07-08 2013-01-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
EP2543372A1 (en) * 2011-07-08 2013-01-09 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for the treatment of liver cancer
JP2014525450A (ja) 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー c−Kitキナーゼ阻害剤としての化合物および組成物
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
US9428732B2 (en) * 2011-12-05 2016-08-30 Primorigen Biosciences, Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
TW201329067A (zh) 2011-12-08 2013-07-16 Amgen Inc 作為gka活化劑之脲化合物
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
BR112014018961A8 (pt) 2012-02-06 2017-07-11 Genentech Inc Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
HK1208233A1 (en) 2012-05-11 2016-02-26 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2890398A4 (en) 2012-08-31 2016-03-09 Five Prime Therapeutics Inc METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R)
MX2015004151A (es) 2012-10-05 2015-07-06 Rigel Pharmaceuticals Inc Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8).
EP2935271B1 (en) * 2012-12-21 2017-10-25 Bristol-Myers Squibb Company Novel substituted imidazoles as casein kinase 1 / inhibitors
CN103936730A (zh) * 2013-01-22 2014-07-23 通化济达医药有限公司 苯磺酰胺噻唑激酶抑制剂
CN103275112A (zh) 2013-05-11 2013-09-04 济南韶远医药技术有限公司 一种利用微反应器连续合成芳基硼酸酯的方法
CA2912568A1 (en) * 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
US20160199372A1 (en) 2013-08-20 2016-07-14 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
EP3265454B1 (en) 2015-03-02 2020-02-26 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845745B2 (en) 2017-03-23 2023-12-19 Clavius Pharmaceuticals, LLC. Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment

Similar Documents

Publication Publication Date Title
JP2018510857A5 (enExample)
JP2018501209A5 (enExample)
JP2019504821A5 (enExample)
CN104755478B (zh) 丝氨酸/苏氨酸激酶抑制剂
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
JP4974437B2 (ja) ファルネシルトランスフェラーゼを阻害する6−[(置換フェニル)メチル]−キノリンおよびキナゾリン誘導体
TW201701879A (zh) Irak4抑制劑組合
JP2017520607A5 (enExample)
JP2010514689A5 (enExample)
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
TW201840549A (zh) 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺
CN108430993A (zh) Tank-结合激酶抑制剂化合物
EA037112B1 (ru) Ингибиторы tgf-
WO2015002754A2 (en) Novel bicyclic bromodomain inhibitors
JP2011503166A5 (enExample)
CN108137590A (zh) 作为mdm2-p53抑制剂的新的螺(3h-吲哚-3,2′-吡咯烷)-2(1h)-酮化合物及其衍生物
JPWO2020231806A5 (enExample)
JP2019503385A5 (enExample)
CA3071760A1 (en) Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
CN105980387A (zh) 丝氨酸/苏氨酸激酶抑制剂
CN112204027A (zh) Erk 抑制剂及其应用
JP2017532360A5 (enExample)
EP3209665A1 (en) Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
EP3713931A1 (en) 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
EP4237086A1 (en) Heterocyclic spiro compounds and methods of use